# Trade Mark Journal No.2026/020 15 May 2026

## WO0000001901555 (5,35,44)

Office of origin: United States of America

Date of International Registration:8 January 2026
Date of designation in the UK: 8 January 2026

International priority date claimed: 4 August 2025 (United States of America) (99319317)

Class 5
  Pharmaceutical preparations for the treatment and prevention of neurologic, genetic, psychologic, and psychiatric diseases and disorders.
Class 35
  Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; business administrative services for medical referrals.
Class 44
  Consultancy in the field of the medical treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome; consultancy in the field of the medical diagnosis of neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome; health care services, namely, providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; health care services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders.

ACADIA Pharmaceuticals Inc.

Representative: Carissa L. Weiss Law Office of Carissa L. Weiss, PLLC, 745 Fifth Avenue, Suite 500, New York NY 10151, UNITED STATES OF AMERICA